Multiple bispecific NK-cell engagers are in pre-clinical development and target NK-cell antigens such as NKG2D, CD16a, MICA, CD16a and CD200,NKp30, Nkp46 and myeloma cell antigens such as CS1, BCMA, CD38 (77–81). This evidence concerns the gene CD38 and plasma cell myeloma.